Astera Labs (ALAB) Financials

Astera Labs delivered another strong quarter in Q1 2026, with revenue growth, solid profitability, and a very large cash cushion. The company posted $308.4 million in revenue, up from $270.6 million in Q4 2025 and $159.4 million in Q1 2025. Net income reached $80.3 million, up sequentially from $44.98 million and well above the $31.8 million earned in the same quarter a year ago.

Profitability remained impressive. Gross profit was $235.1 million, which implies a gross margin of about 76.2% for the quarter. Operating income came in at $61.8 million, and pretax income was $73.4 million. While operating expenses were elevated, they were still well covered by gross profit, showing that the business is scaling efficiently.

The balance sheet remains a major strength. As of March 31, 2026, Astera Labs had $148.3 million in cash and equivalents and $1.04 billion in short-term investments, for total cash and investments of roughly $1.18 billion. Against just $165.3 million in total liabilities, the company continues to have a very conservative financial position.

Cash generation was also healthy. The company produced $74.6 million in operating cash flow in Q1 2026, even after a $59.1 million use of working capital. That’s down from $95.3 million in Q4 2025, but still a solid result given the company’s growth profile.

At the same time, investing activity was heavy. Astera Labs used $94.0 million in investing cash flow during the quarter, including $156.6 million of investment purchases, $65.0 million in acquisitions, and $7.6 million of capital expenditures, partially offset by $137.8 million of investment sales/maturities. This suggests the company is still deploying capital aggressively, likely to support growth and strategic expansion.

Looking at the longer trend, the business has dramatically improved since 2024. In Q1 2024, Astera Labs generated a loss of $92.9 million and just $3.7 million of operating cash flow. By Q1 2025 and Q1 2026, the company had become consistently profitable and much more cash-generative. Revenue also expanded sharply over that period, rising from $65.3 million in Q1 2024 to $308.4 million in Q1 2026.

• Revenue growth remains very strong, with Q1 2026 sales up 93.0% year over year from $159.4 million to $308.4 million.
• Net income continues to scale higher, reaching $80.3 million in Q1 2026 versus $31.8 million in Q1 2025 and a loss in Q1 2024.
• Gross margin is high, with Q1 2026 gross profit of $235.1 million on $308.4 million of revenue.
• The balance sheet is exceptionally strong, with about $1.18 billion in cash and short-term investments against $165.3 million in total liabilities.
• Operating cash flow stayed positive at $74.6 million in Q1 2026.
• Long-term earnings trend is clearly improving, moving from losses in early 2024 to sustained profitability in 2025 and 2026.
• Short-term investments remain the bulk of liquidity, which is supportive, but investors should watch interest-rate and market-value sensitivity.
• Acquisition activity was meaningful at $65.0 million in Q1 2026, which could help growth but also adds integration risk.
• Working capital was a headwind in Q1 2026, reducing operating cash flow by $59.1 million.
• Investing cash outflows remain large, reflecting continued capital deployment and a less free-cash-flow-friendly quarter.

Bottom line: Astera Labs looks financially healthy and still in a strong growth phase. Revenue and earnings are rising quickly, the company is generating cash, and the balance sheet is flush. The main items to monitor are the pace of operating expense growth, the size of acquisition-related spending, and whether working capital headwinds become persistent.